Abstract
Genes whose expression is affected in a consistent manner by GWAS-identified risk variants and the disease process, constitute preferred drug targets. We herein combine integrated cis-eQTL analysis in 27 blood cell populations and 43 intestinal cell types of the ileum, colon and rectum, and information on gene expression in patients, to search for putative drug targets for inflammatory bowel disease (IBD). We detect >95K cis-eQTL that affect >13K e-genes and cluster in >24K regulatory modules (RM). We uncover matching RM for 140 risk loci, implicating >300 e-genes not previously connected to IBD, and find 152 IBD-matching e-genes whose expression is perturbed in the blood or gut of patients. We identify entrectinib, a small molecule inhibiting the NRLP3 inflammasome by binding NEK7, as a promising repurposing candidate for IBD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was conducted with funding from the SYSCID H2020 grant (ref. 733100, the MyQuant (ref. 30770923) and BRIDGE (O.0006.22 RG3124) projects from the Excellence of Science (EOS) program (FNRS, Federation Wallonie-Bruxelles and FWO, Flemish Community), the CLIMAX (WELBIO CR 2022 A) project from WELBIO (Walloon Region), the RHEAQT (T.0096.19) and IBD GI Seq (T.0190.19) projects from the FNRS (Federation Wallonie Bruxelles), the ARC RHEACT WITH HSPC project from the University of Liege. Computational resources have been provided by the Consortium des Equipements de Calcul Intensif (CeCI), funded by the Fonds de la Recherche Scientifique de Belgique (F.R.S. FNRS) under Grant No. 2.5020.11 and by the Walloon Region.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained prior to donation in agreement with the recommendations of the declaration of Helsinki for experiments involving human subjects. The experimental protocol was approved by the Ethics committee of the CHU Liege (reference number: 2017/214).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
